SHPW yields 666.67% · ABBV yields 3.06%● Live data
📍 SHPW pulled ahead of the other in Year 1
Combined, SHPW + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHPW + ABBV for your $10,000?
Shapeways Holdings, Inc. facilitates the design, manufacture, and sale of 3D printed products in the United States, Europe, and internationally. The company offers an end-to-end digital manufacturing platform on which the users can transform digital designs into physical products under the Otto brand. It provides additive manufacturing services, such as 3D printing, rapid prototyping, and design services; and traditional manufacturing services, including injection molding, sheet metal, urethane and vacuum casting, CNC machining, and machine tooling. It also offers selective laser sintering materials, which include nylon 12, thermoplastic polyurethane, nylon 11, nylon 6 mineral filled, and polypropylene; binder jetting materials consisting of stainless steel and sandstone; multi-jet fusion materials; stereolithography materials, such as accura 60, accura xtreme, and accura xtreme white 200; selective laser melting material, including aluminum; material jetting materials, such as fine detail plastic, multi-color polyjet, and high definition full color; and wax casting materials comprising copper, platinum, gold, silver, bronze, brass, rhodium plated brass, and gold plated brass. The company serves the medical, consumer, robotics, architecture, aerospace, gaming, drones, education, and jewelry industries. Shapeways Holdings, Inc. was founded in 2008 and is based in Long Island City, New York.
Full SHPW Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.